Author Archive for Pharmboy

Baxter’s Spinoff

Reminder: Pharmboy and Ilene are available to chat with Members, comments are found below each post.

Baxter Int. (BAX) is splitting off its BioSciences division into a new company called Baxalta. Shares of Baxalta will be given as a tax-free dividend, in the ratio of one to one, to BAX holders on record on June 17, 2015. That means, if you want to receive the Baxalta dividend, you need to buy the stock this week (on or before June 12).

The Baxalta Spinoff

By Ilene with Trevor of Lowenthal Capital Partners and Paul Price

In its recent filing with the SEC, Baxter provides:

“This information statement is being furnished in connection with the distribution by Baxter International Inc. (Baxter) to its shareholders of approximately 80.5% of the outstanding shares of common stock of Baxalta Incorporated (Baxalta), a wholly owned subsidiary of Baxter that will hold directly or indirectly the assets and liabilities associated with Baxter’s biopharmaceuticals business. To implement the distribution, Baxter will distribute approximately 80.5% of the shares of Baxalta common stock on a pro rata basis to the Baxter shareholders in a manner that is intended to be tax-free for U.S. federal income tax purposes.”

“As a result of the separation, each Baxter shareholder will receive one share of Baxalta common stock for every Baxter share of common stock held on June 17, 2015, the record date for the distribution.”

Trevor Lowenthal at Lowenthal Capital Partners, Paul Price and I have been reviewing Baxter and its upcoming spinoff of Baxalta. We believe that the spinoff will unleash value from the Baxalta bioscience division of the company and that the sum of the BAX parts will prove to be greater than the whole.  Baxalta should benefit from growing market penetration for Advate, the number one selling therapy in its hemophilia franchise, along with the approval of important new products. This should enhance long-term value for current BAX shareholders as Baxalta's new products hit the market and as the independent company gets priced more in line with its growth prospects. 

In April, Trevor Lowenthal shared his thoughts on BAX in Going Long On Baxter For An Optimistic 2016. To summarize:

  • Baxter has experienced several lackluster quarters, but the company's revenues are growing and its positive outlook

continue reading

Can Protalix BioTherapeutics Deliver?

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Here's an update on a stock that Pharmboy is well familiar with, PLX. Pharmboy provided his thoughts for this article which was published by Lowenthal Capital Partners, and which I contributed to them. One reader asked the question: While PLX has sufficient cash for another year's operation, it needs to conserve resources and will likely need to raise money in the future. Would you care to venture a guess as to when you believe they will raise money (and what type vehicle they will use)?

Pharmboy's response: They will sell stock, and my guess is in 4Q15. I agree--selling stock is probably on the horizon sooner rather than later. Let's hope they get the stock moving higher before then. ~ Ilene 

Can Protalix BioTherapeutics Deliver?

Protalix BioTherapeutics is a small biotech company that is working on developing clinically superior versions of recombinant therapeutic proteins for the treatment of genetic disorders, such as Gaucher's disease (GD) and Fabry disease (FD). It is based in Israel and was founded in 1993.

PLX is using its plant cell-based system, ProCellEx, to produce recombinant proteins with competitive advantages over existing recombinant protein therapies for indications that are known to be amenable to therapeutic protein replacement. The ProCellEx system is more robust and less expense than mammalian cell and yeast cell-based processes. Further, the ProCellEx system may produce biotherapeutics that can be delivered orally.

Currently, PLX has one recombinant therapeutic protein product on the market called taliglucerase alfa. Taliglucerase alfa is used for enzyme replacement therapy in Type 1 GD. It is being marketed with Pfizer (NYSE:PFE) under the brand name Elelyso.

PLX also has four potential recombinant protein drugs in early stages of development. PLX's active investigational programs address Gaucher's disease, Fabry disease, immune and inflammatory diseases such as inflammatory bowel disease, and cystic fibrosis.

While PLX has sufficient cash for another year's operation, it needs to conserve resources and will likely need to raise money in the future.

Given the comparative cost effectiveness and ease of use of ProCellEx in generating large quantities of therapeutic proteins, with the potential for effective oral delivery, I believe PLX is an interesting biotech speculation.

continue reading

Big Pharma’s Business Model is Changing

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Understanding the new normal of a business model is key to the success of any company.  The managment of companies need to adapt to the changing demand, but first they must recognize what changes are taking place.  Big Pharma's business model is changing rapidly, and much like the airline industry, there will be but a handful of pharma companies left at the end of this path.

Most Big Pharma companies have traditionally done everything from research and development (R&D) through to commercialisation themselves. Research was proprietary, and diseases were cherry picked on the back of academic research that was done using NIH grants.  This was in the heyday of research, where multiple companies had drugs for the same target (Mevocor, Zocor, Crestor, Lipitor), and could reap the rewards on multiple scales.  However, in the coming years, this research to commercialization model will no longer work for many organizations. If Big Pharma is to prosper, it will need to reduce costs while improving its R&D selectivity AND productivity.

The mid to late 1990s was the hayday of Big Pharma drug approvals.  Research was humming, treatments for diseases with large populations were rolling out, and pricing was favorable for reaping billions.  Big Pharma saw pharmacy benefit mangers as the wave of the future, as Pharma could sell their 'perferred' drugs through their networks, much like health insurance.  The bigger the PBM, the better off one would be, and Mevco (owned by Merck at the time), was growing rapidly!  Even if a drug was going generic, the PBM's would continue to sell the branded drugs for a premium, their own branded drugs!  All was good in the drug world.  Then the winds of change hit, where 2007/8 caused a backlash not only in the financial world, but also in pharma.  PBMs were sold off, as companies were accused of script manipulation and unfair pricing.  In addition, the margins were shrinking as the likes of TEVA, Dr. Reddy, and others were gaining market share.

Then, the 'Patent Cliff' started rearing its ugly head, and those big revenue streams were drying up.  In 2010, I wrote 'The Calm Before the Storm" article on PSW, noting that the for Big Pharma to continue, it needs…
continue reading

About Opko’s recent surge higher…

Reminder: Pharmboy and Ilene are available to chat with Members, comments are found below each post.

My friend Trevor at Lowenthal Capital Partners entitles his article on Opko Health (OPK) "Why Shorting Opko Health Makes No Sense After The Q1 2015 Earnings Report." So I asked him, "Why that title? Why not just say "Going Long OPK," or "OPK: Finally Earns Bubble Valuation, A Keeper!"? If you examine the key statistics, you will not fall in love with this stock. And one look at the chart explains Trevor's title. ~ Ilene

Six month chart (Yahoo)

But Trevor likes the shares, preferably a little cheaper, and explains why in his article, Why Shorting Opko Health Makes No Sense After The Q1 2015 Earnings Report



  • Opko Health continues to impress on many fronts.
  • The Q1 2015 earnings report confirmed key developments related to 4Kscore Test reimbursement and NDA filing for Rayaldee, and the market is taking notice.
  • Management continues to buy shares on the open market. [Go to insider cow, look up OPK.]
  • For these reasons, shorting Opko Health does not seem to be a viable investment strategy.


I am a buyer of Opko at current price levels, as I believe there is considerable upside ahead. It seems that Opko is entering a period in which any number of developments could create shareholder optimism and spark a rally (which we are seeing now). And given the company's long-term growth potential looks strong, I do not believe establishing a short position in Opko is a viable investment strategy. Perhaps looking for short plays elsewhere in biotech is a safer bet.

There's truly been a lot of insider buying of Opko shares by the CEO indirectly as Frost Gamma Investments Trust. The chart below is from Insider Cow, the blue bars represent insider buying.  


2015 – Biotech Fever

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

PSW Members – well, what a year for biotechs!   The Biotech Index (IBB) is up a whopping 40%, beating the S&P hands down!  The healthcare sector has had a number of high flying IPOs, and beat the Tech Sector in total nubmer of IPOs in the past 12 months.  What could go wrong?

Phil has given his Secret Santa Inflation Hedges for 2015, and since I have been trying to keep my head above water between work, PSW, and baseball with my boys…it is time that something is put together for PSW on biotechs in 2015.

Cancer and fibrosis remain two of the hottest areas for VC backed biotechs to invest their monies.  A number of companies have gone IPO which have drugs/technologies that fight cancer, including JUNO Therapeutics (JUNO), Bellicum Pharmaceuticals (BLCM), Kite (KITE), Immune Design (IMDZ) in 2014.  On the other side, fibrosis can be a side effect of cancer as well as involved in a host of other diseases (IPF, NASH).  Fibrosis is less understood, and therefore can be harder to treat, and yet a number of high flying companies have been bought due to their drugs (GILD buying Arresto, Roche buying Intermune), and therefore fibrosis remains a very hot area.  One company in this space that just IPO'd is Fibrogen (FGEN). 

Cancer Company to Consider

JUNO Therapeutics (JUNO): Juno was founded on the backs of cancer researchers at Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute.  With more than $300M in funding, the stock IPO'd at 45% above its original midpoint, making it the year's second highest premium behind Castlight Health.  The company raised $265 million, giving it a >$2 billion valuation.  This made it the largest biotech IPO in at least 15 years both by deal size and market cap.  What Dendreon could have done had it picked the right cancer to use its techology!

JUNO's technology is chimeric antigen receptor, or CAR-t for short.  CAR-t technology is where the persons own T-cells (a white blood cell) are harvested and modified to fight cancer cells.  The technology has tested positive early…
continue reading

Biotechs & Bubbles

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Well PSW Subscribers….I am still here, barely.  From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired….buy a small amount.

First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices.  Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment.  Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer.  For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND  other drugs must often be used with it adding to the cost.  So, for more convenience and a better response rate….why not go for the best drug out there for HepC?  Other drugs are increasing in price, and the diagram below from Bloomberg shows that even Viagra has gone up in price considerably over the past 7 years.  Big pharma has infrastructure it needs to pay for, as well as investors that like outsized returns.  Biotechs, on the other hand, have drugs in clinic that can make or break the company.  Therefore, doing homework on these companies is critical, and understanding the science is imperative. 

The trend in industry (biotechs especially), is to go after the harder to treat diseases, which then also command a premium IF the drug is successful.  BMY bought Amira Pharmaceuticals for >$370M on the chance that their IPF drug (LPA1 receptor antagonist) works in these patients (life expectancy is 5 yrs).  Gilead bought Arresto for >$200M for the same indication (IPF), but a different mechanism of action (LOXL2 monoclonal antibody).  Both of these companies were finishing Phase 1…which means there was NO efficacy seen!!!  Intermune's drug Esbriet is expected to cost about $60k/yr, so if either of these drugs from BMY or GILD hit, and are better than Esbriet, then one can expect their prices to be higher!

So, which companies should be the focus? Well, one…
continue reading

Here We Go Again – Pharma & Biotechs 2014

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Ladies and Gentlemen, hobos and tramps,
Cross-eyed mosquitoes, and Bow-legged ants,
I come before you, To stand behind you,
To tell you something, I know nothing about.

And so the circus begins in Union Square, San Francisco for this weeks JP Morgan Healthcare Conference.  Will the momentum from 2013, which carried the S&P Spider Biotech ETF to all time highs, carry on in 2014?  The Biotech ETF beat the S&P by better than 3 points.

As I noted in my previous post, Biotechs Galore – IPOs and More, biotechs were rushing to IPOs so that venture capitalists could unwind their holdings (funds are usually 5-7 years), as well as take advantage of the opportune moment when the reward is all about risk.  In our current low interest rates environment, investors are starved for better returns, and the perfect place for those gains are high risk/reward biotechs.  A total of 46 companies went public in 2013 (16 more after my initial write-up), and 80% of them were ABOVE their IPO pricing!  The entire IPO 2013 class was up 48%!  48%! I know that cutting edge science is exciting, BUT when a company is valued for a potential treatment that still have a long way to go for final approval, I want to sell you a wing and a prayer for an idea I have that cures something I cannot tell you about….

Science is an exciting area to be apart of, and it is our hopes in this field to make an impact on a patient's life (for the better of course), but the gradiosity of the market sentiment for these biotechs makes me want to give everyone a Valium!  There is some very good science in the companies that went public, and those were covered in my previous post.  Now, a few more of those fledglings will be discussed.

Entana Pharmaceuticals (ENTA) – is riding the hepititis C wave that has engrossed the pharmaceutical industry the past few years.  Vertex (VRTX), Bristol (BMY), Merck (MRK), Gilead (GILD), JnJ (JNJ), and Abbvie (ABBV) are all in the space.  Even so, a few biotechs…
continue reading

Biotech Galore – IPOs and More

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Come and get it!  Read all about it! Biotechs, biotechs and more biotechs to buy buy buy for your portfolio! To date, almost 30 biotech companies have hit the market.  Most of the time, there are fewer than 10-12!

For the last five years, biotechs have had issues obtaining offer prices above expectations.  In 2013, that trend looks to be broken.  According to BiotechNow, the offer prices are 4% above expectations!  In addition, biotechs are going public with little more than a wing and a prayer (pre-clinical or Phase 1 data only).  Really? What this means is that the drug or technology looks good in mice, rats, or dogs, etc, but there is no smidgen of evidence that it will work in humans. That's what is called an appitite for RISK!

Of the thirty or so companies, several came out of the gate and have done quite well (figures from BiotechNow):


Those are some impressive numbers, but what do the companies have that make them attractive?

Epizyme (EPZM) – One of the 'darling' companies of the IPO market, EPZM has moved into the heavens with its stock price, and a market cap of almost $1B for two Phase 1 programs that look very interesting, but have no validated human data.

The company is working on cancer, and more specifically histone methyltransferases (HMTs referred to hereafter).  This family of enzymes are involved in the winding and unwinding of DNA.  So, in cancer, if the specific enzyme that unwinds DNA is over expressed (more of it), then cancer cells can multiply faster.  EPZM is looking at two specific HMTs, DOT1L and EZH2. 

DOT1L inhibitor, EPZ-5676, is a small molecule inhibitor of created for the treatment of acute leukemias in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r). Due to the translocation, DOT1L is recruited to specific locations in the chromosome where it would not normally be present. As a result, DOT1L causes inappropriate methylation at these locations, which results in the increased expression of genes causing…
continue reading

Pet Meds – Still Chugging Along

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Readers of PSW Chat know that I have long been a fan of pet companies, especially those with branded products that owners pay out of pocket to keep their animals healthy.  The industry continues to expand, whether it is food, supplies, medicines or purchasing animals themselves.  In fact, from 1994 to 2012, the industry has tripled from $17 to $53B.  For 2013, the growth estimates are a modest 4.1%.

  2012 2013
U.S. Pet Industry Expenditures (from APPA) in $B
Food 20.6 21.3
Supplies/OTC Meds 12.7 13.2
Vet Care 13.7 14.2
Animal Purchase 2.2 2.3
Pet Services (Grooming/Boarding) 4.2 4.5

Getting a foold suppliment or additive is not really that hard in the industry, but the branded medications/vaccines/antiboitics are much like the human path to the market.  Rigid clinical trials are done, and today over 300 products are approved for use in companion animals (dogs, cats and horses).  With most of the revenues coming from out-of-pocket funds, the market is ripe for smaller competitors to enter and be swallowed up by larger companies.

In the past few months, Pfizer (PFE) has spun off their animal health division Zoetis (ZTS), and a pet biotech Aratana Therapeutics (PETX) went public.  Merck, Eli Lilly, andSanofi have their pet divisions as well, and David Krempa (Morningstar) calls the animal health industry “a really attractive business to be in, more so than human pharma.”

It is time to look at a few of these public companies, and at PSW (in member chat), positions were intiated in ZTS and PETX.

Zoetis (ZTS) – is a global manufacturer of >300 medicines and vaccines products and currently has a market cap of about $15.3B (forward…
continue reading

Give Them an Inch, They Will Take a Mile

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Well, well, well….it is good to know that there are others in the scientific arena who believed that YMI Bioscience's data (cough – Gilead) is a better drug than Incyte's Jakafi.  Now, the definitive data are still unknown, but there was enough evidence from a Phase 2 trial to take a small risk for a huge reward.  So, let's forget about Apple (AAPL), and do nothing but biotechs from now until Congress passes universal health care coverage for prescriptions….and drive the prices down so that research and development is no longer feasible to conduct in the US. Even Seattle Genetics (SGEN) has been on a tear as of late, and I expect more from it in the future. Its future may be short lived, as it is my premise that it will be bought out for its technology and pipeline.

At PSW we continue to sell premium against a position.  We have been doing this for many months, especially against a basket of biotechs that we have been buying and holding (CRIS, PLX, EXEL, and others). 

Let's take a look at a few other companies pipelines, and see if they are worthy of our funds.

Merrimack Pharmaceuticals (MACK) – the company was founded in 2000 and went IPO at the end of March 2012 for $7.  The IPO, in which all outstanding shares of Merrimack's convertible preferred stock were converted into 66,255,529 shares of common stock and in which Merrimack issued 15,042,459 new shares of common stock, yields a market cap of $591M.  Cash and equivalents on hand were about $80M, and a loan guarantee they note should get them into 2014, but raising money is something that Biotechs do on a regular basis.  So, we will not hold our breath.  In the last six months, insider ownership has increased by 2.8%, while institutional ownership has increased by a staggering 34% (here).



The company's lead drug is MM-398, which is a nanoliposomal encapsulation of the conventional chemotherapy Camptostar (irinotecan; Pfizer). 

is put in to make it last longer in the body as well as potentially…
continue reading


Zero Hedge

Paper Gold Dilution Hits 294x As Comex Registered Gold Drops To New All-Time Low

Courtesy of ZeroHedge. View original post here.

Submitted by Tyler Durden.

One week ago, gold market observers were surprised when in the span of four days, gold held in the JPM Comex vault declined by nearly 50%, starting on November 16 when the 668,498 ounces held in the vault below 1 Chase Manhattan Plaza declined precipitously to just 347,899 ounces, a new all time low.

Furthermore, as of the latest Comex activity update, on Friday the Registered gold held by JPM dropped another 2,802 ounces to a record low and virtually negligible 7,975 ounces, essentially equivalent to zero as shown in the chart below, even as JPM's eligible gold has also been seeing a substantial decline in recent months.


more from Tyler

Phil's Favorites

China's rebalancing timetable


China’s rebalancing timetable

Courtesy of Michael Pettis

We often read in the press rather alarming stories about the rise of an ugly and belligerent nationalism in China, but while these stories are certainly very real, after the November 13 bombings in Paris I was struck by a very different kind of Chinese behavior. A lot of young people that I know in Beijing – high school and college students, young professionals, musicians, etc. – were horrified by the violence that occurred in Paris and very eager to express a real sympathy for Parisians, which they did in the ways that young people express themselves today, via smart phones, social media, and all the other things that wouldn’t have occurred to me. I saw an awful lot of...

more from Ilene

All About Trends

Mid-Day Update

Reminder: David is available to chat with Members, comments are found below each post.

Click here for the full report.

To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David

Market News

News You Can Use From Phil's Stock World


Financial Markets and Economy

World's Biggest Pension Fund Loses $64 Billion Amid Equity Rout (Bloomberg)

The worlds biggest pension fund posted its worst quarterly loss since at least 2008 after a global stock rout in August and September wiped $64 billion off the Japanese asset managers investments.

It's starting to look like negative interest rates might do the opposite of what they're supposed to (Business Insider)

The European Central Bank is expected to cut interest rates deeper into negative territory this week as it attempts to ...

more from Paul

Kimble Charting Solutions

Crude Oil Market As Oversold As 1999 Lows

Courtesy of Chris Kimble.

Crude Oil is quite simply the most important commodity on the planet. But volatility with Crude Oil prices emerges every time there is conflict in oil producing nations or an economic slowdown.

And this has led to some pretty big swings in Crude Oil prices over the past several years.

But the latest swing lower is nearing a moment of truth. In fact, this decline may be the most important swing lower of the 2000’s.

Why?  Because oil prices are currently testing a key price support level comprised of the 2004 breakout level (above the 1990 highs) and the 2009 price lows – see red circles and line. In fact, this price support area also marks the 23.6 Fibonacci support level (from the 1999 lows to 2008 highs).  AND crude oil is as oversold as it was back at the 1999 price lows!

But that’s no...

more from Kimble C.S.


Swing trading portfolio - week of November 30th, 2015

Reminder: OpTrader is available to chat with Members, comments are found below each post.


This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...

more from OpTrader

Digital Currencies

The Bitcoin Universe Explained

Courtesy of ZeroHedge. View original post here.

As evidenced by the Greek, Chinese, and now Argentine 'jumps', the world remains increasingly aware of the inevitable worth of fiat currencies and fears the desperate acts of governments as the react to that reality (and is looking for alternatives).

This infographic explains the wide ranges of the Bitcoin universe, accompanied with quotes from some of its best-known business leaders.

Courtesy of: Visual Capitalist ...

more from Bitcoin

Chart School

Greatest risk to the stock market is?

Courtesy of Read the Ticker.

Nope it is not interest rates, nope it is not Donald Trump, it is!

It is the CRUDE OIL crash, simple!

Jim Willie has good comments in the first 40 min of this pod cast.

Energy company ...
- Debt is blowing up (See energy element of HYG).
- Hedging at oil $100 is coming to an end.
- Iran coming back to the market, more supply.
- Saudi still providing massive supply.
- Oil tankers holding oil parked in the ocean are coming in to harbor to unload
- US dollar strength supports lower oil prices
- World wide DEMAND slump for energy or deflation.
- More oil being sold outside the US Dollar
- The Oil futures can not be manipulated easily as folks actually ...

more from Chart School


Sector Detector: Bulls wrest back control of market direction, despite global adversity

Reminder: Sabrient is available to chat with Members, comments are found below each post.

Courtesy of Sabrient Systems and Gradient Analytics

Some weeks when I write this article there is little new to talk about from the prior week. It’s always the Fed, global QE, China growth, election chatter, oil prices, etc. And then there are times like this in which there is so much happening that I don’t know where to start. Of course, the biggest market-moving news came the weekend before last when Paris was put face-to-face with the depths of human depravity and savagery. And yet the stock market responded with its best week of the year. As a result, the key issues dominating the front page and election chatter have moved from the economy and jobs to national security and a real war (rather than police ...

more from Sabrient


PSW is more than just stock talk!


We know you love coming here for our Stocks & Options education, strategy and trade ideas, and for Phil's daily commentary which you can't live without, but there's more! features the most important and most interesting news items from around the web, all day, every day!

News: If you missed it, you can probably find it in our Market News section. We sift through piles of news so you don't have to.   

If you are looking for non-mainstream, provocatively-narrated news and opinion pieces which promise to make you think -- we feature Zero Hedge, ...

more from Promotions


Whitney Tilson On LL, EXACT, And Martin Shkreli


Whitney Tilson On LL, EXACT, And Martin Shkreli

Courtesy of Value Walk

1) The shares of one of my largest short positions (~3%), Exact Sciences, crashed by more than 46% yesterday. Below is the article I published this morning on SeekingAlpha, explaining why I think it’s still a great short and thus shorted more yesterday. Here’s a summary:

  • The U.S. Preventative Services Task Force’s Colorectal Cancer Screening Draft Recommendation issued yesterday is devastating for Exact Sciences’ only product, Cologuard.
  • I think this is the beginning of the end for the company.
  • My price target for the stock a year from now is $3, so I shorted more yes...

more from ValueWalk


Baxter's Spinoff

Reminder: Pharmboy and Ilene are available to chat with Members, comments are found below each post.

Baxter Int. (BAX) is splitting off its BioSciences division into a new company called Baxalta. Shares of Baxalta will be given as a tax-free dividend, in the ratio of one to one, to BAX holders on record on June 17, 2015. That means, if you want to receive the Baxalta dividend, you need to buy the stock this week (on or before June 12).

The Baxalta Spinoff

By Ilene with Trevor of Lowenthal Capital Partners and Paul Price

In its recent filing with the SEC, Baxter provides:

“This information statement is being ...

more from Pharmboy

Mapping The Market

An update on oil proxies

Courtesy of Jean-Luc Saillard

Back in December, I wrote a post on my blog where I compared the performances of various ETFs related to the oil industry. I was looking for the best possible proxy to match the moves of oil prices if you didn't want to play with futures. At the time, I concluded that for medium term trades, USO and the leveraged ETFs UCO and SCO were the most promising. Longer term, broader ETFs like OIH and XLE might make better investment if oil prices do recover to more profitable prices since ETF linked to futures like USO, UCO and SCO do suffer from decay. It also seemed that DIG and DUG could be promising if OIH could recover as it should with the price of oil, but that they don't make a good proxy for the price of oil itself. 


more from M.T.M.

Help One Of Our Own PSW Members

"Hello PSW Members –

This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible.  Feel free to contact me directly at with any questions.

Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts.  After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.)  Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.

Thank you for you time!

FeedTheBull - Top Stock market and Finance Sites

About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>

As Seen On:

About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>